Publications by authors named "H Devarbhavi"
Cholestatic DILI is an important and frequently challenging differential diagnosis in patients presenting with elevated liver tests with predominant elevation in alkaline phosphatase. A number of competing etiologies need to be ruled out, such as hepatobiliary malignancy, choledocholithiasis, cholestatic forms of viral hepatitis, cholestasis of sepsis, primary and secondary cholangitis, and right-sided cardiac failure to name a few. Important advances have occurred in the understanding and knowledge of the clinical phenotypes, new etiological agents, risk factors, pathophysiology, and genetic determinants of drug-induced cholestasis since the last review on drug-induced cholestasis was published in Hepatology in 2011.
View Article and Find Full Text PDFArticle Synopsis
- MAFLD (Metabolic Dysfunction-Associated Fatty Liver Disease) is becoming more common, and it can lead to serious liver problems called MAFLD-ACLF, but what affects patient recovery isn't fully known yet.
- In a study, researchers looked at data from patients with MAFLD-ACLF to understand their health conditions and see who survived after 90 days, finding that about 51% of patients did survive.
- They discovered new scoring systems to better predict survival, which included factors like diabetes and the causes of liver damage, and these new scores worked better than older ones.
Drug-induced liver injury in patients with underlying liver disease.
Clin Liver Dis (Hoboken)
June 2024
Article Synopsis
- The study aimed to evaluate the relationship between ammonia levels and liver-related complications (LRCs) in patients with acute-on-chronic liver failure (ACLF).
- Higher ammonia levels were found in ACLF patients with LRCs, especially those experiencing overt hepatic encephalopathy (HE) and ascites, but not bacterial infections.
- Baseline arterial ammonia levels were identified as an independent predictor of 30-day mortality, but they did not predict the development of new LRCs within that timeframe.
Background: Hormonal oral contraceptive (OC) agents such as estrogen or progesterone, either as single agents or in combination, and a non-hormonal drug like ormeloxifene are used for various conditions. However, estrogen and progesterone-containing OC as well as ormeloxifene are seldom associated with hepatotoxicity. We prospectively studied the clinical, demographic, liver injury pattern, complications, and outcome of the hepatotoxicity from OC and ormeloxifene.
View Article and Find Full Text PDF